- Home
- TPIC vs NOTV Comparison
TPIC vs NOTV Comparison
Compare TPIC & NOTV Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- TPIC
- NOTV
- Stock Information
- Founded
- TPIC 1968
- NOTV 1974
- Country
- TPIC United States
- NOTV United States
- Employees
- TPIC N/A
- NOTV N/A
- Industry
- TPIC Industrial Machinery/Components
- NOTV Biotechnology: Pharmaceutical Preparations
- Sector
- TPIC Industrials
- NOTV Health Care
- Exchange
- TPIC Nasdaq
- NOTV Nasdaq
- Market Cap
- TPIC 58.4M
- NOTV 62.5M
- IPO Year
- TPIC 2016
- NOTV 1997
- Fundamental
- Price
- TPIC $0.79
- NOTV $2.04
- Analyst Decision
- TPIC Hold
- NOTV Strong Buy
- Analyst Count
- TPIC 7
- NOTV 1
- Target Price
- TPIC $1.68
- NOTV $5.00
- AVG Volume (30 Days)
- TPIC 475.4K
- NOTV 412.3K
- Earning Date
- TPIC 08-11-2025
- NOTV 08-06-2025
- Dividend Yield
- TPIC N/A
- NOTV N/A
- EPS Growth
- TPIC N/A
- NOTV N/A
- EPS
- TPIC N/A
- NOTV N/A
- Revenue
- TPIC $1,373,242,000.00
- NOTV $480,402,000.00
- Revenue This Year
- TPIC $10.73
- NOTV $4.99
- Revenue Next Year
- TPIC $5.56
- NOTV $5.39
- P/E Ratio
- TPIC N/A
- NOTV N/A
- Revenue Growth
- TPIC 3.05
- NOTV N/A
- 52 Week Low
- TPIC $0.64
- NOTV $1.15
- 52 Week High
- TPIC $5.15
- NOTV $6.48
- Technical
- Relative Strength Index (RSI)
- TPIC 39.96
- NOTV 50.48
- Support Level
- TPIC $0.78
- NOTV $2.01
- Resistance Level
- TPIC $0.91
- NOTV $2.44
- Average True Range (ATR)
- TPIC 0.07
- NOTV 0.19
- MACD
- TPIC 0.00
- NOTV 0.03
- Stochastic Oscillator
- TPIC 27.67
- NOTV 50.69
About TPIC TPI Composites Inc.
TPI Composites Inc is engaged in manufacturing composite wind blades. The company operates in wind energy and transportation industries where it manufactures structures for a bus, rail, theme parks, and trucks. Geographically the segments are divided into the U.S, Asia, Mexico, EMEA and India where the Mexico segment derives a majority of revenue.
About NOTV Inotiv Inc.
Inotiv Inc is a pharmaceutical development company specializing in nonclinical and analytical drug discovery, development services to the pharmaceutical, chemical, and medical device industries. It operates in two segments; Discovery and Safety Assessment (DSA) and Research Models and Services (RMS). Through the DSA segment, the company supports the discovery, nonclinical development, and clinical development needs of researchers and clinicians for small molecule drug candidates, biotherapeutics, and biomedical devices. Through the RMS segment, the company offers access to a wide range of small and large research models for basic research, drug discovery, development, and specialized models for specific diseases and therapeutic areas. The company earns maximum revenue from RMS Segment.